M. E. Long

发表

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

D. Gustafson, A. Merz, Erica L. Bradshaw, 2005, Cancer Chemotherapy and Pharmacology.

Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.

D. Gustafson, Erica L. Bradshaw, J. Zirrolli, 2005, Journal of pharmaceutical and biomedical analysis.

Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: implications for pharmacokinetics in multiple dosing regimens.

D. Gustafson, M. E. Long, 2001, Chemico-biological interactions.

Pharmacokinetics of combined doxorubicin and paclitaxel in mice.

D. Gustafson, A. Merz, M. E. Long, 2005, Cancer letters.

Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.

D. Gustafson, T. Colombo, M. E. Long, 2002, Journal of pharmaceutical sciences.

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

D. Gustafson, M. Duncan, S. Eckhardt, 2003, Cancer Chemotherapy and Pharmacology.

A physiologically based pharmacodynamic analysis of hepatic foci within a medium-term liver bioassay using pentachlorobenzene as a promoter and diethylnitrosamine as an initiator.

R. S. Thomas, R. Conolly, R. S. Yang, 2000, Toxicology and applied pharmacology.

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

K. Kelly, P. Bunn, A. Baron, 2004, Clinical Cancer Research.

Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay.

Raymond S. H. Yang, Russell S. Thomas, M. Andersen, 2003, Toxicological sciences : an official journal of the Society of Toxicology.

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo

D. Ross, D. Siegel, J. Kepa, 2003, Journal of Pharmacology and Experimental Therapeutics.

Evidence for hepatocarcinogenic activity of pentachlorobenzene with intralobular variation in foci incidence.

R. S. Thomas, R. S. Yang, D. Gustafson, 1998, Carcinogenesis.

Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma.

G. Ogilvie, M. J. Fettman, D. Gustafson, 2006, American journal of veterinary research.

Comparative hepatocarcinogenicity of hexachlorobenzene, pentachlorobenzene, 1,2,4,5-tetrachlorobenzene, and 1,4-dichlorobenzene: application of a medium-term liver focus bioassay and molecular and cellular indices.

R. S. Thomas, D. Gustafson, M. E. Long, 2000, Toxicological sciences : an official journal of the Society of Toxicology.